Full text is available at the source.
Abstract
A woman in her mid-20s developed symptoms after receiving 4 dose-escalated subcutaneous injections of an unverified product reported to contain retatrutide.
- Persistent nausea, vomiting, and diarrhea occurred despite treatment with intravenous fluids and antiemetics.
- No alternative medical causes were identified through blood tests, urinalysis, abdominal ultrasound, and MRI.
- Symptoms began to improve 2 days after hospital admission and resolved within 1 week.
- The Naranjo score of 7 suggests a probable link between the injections and her symptoms.
- This case highlights the potential risks of unverified substances marketed in wellness settings, which may not be disclosed in standard medication histories.
Simplified